Second malignancies after multiple myeloma: from 1960s to 2010s
- 22 March 2012
- journal article
- review article
- Published by American Society of Hematology in Blood
- Vol. 119 (12), 2731-2737
- https://doi.org/10.1182/blood-2011-12-381426
Abstract
Based on small numbers, recent reports from 3 randomized trials have consistently demonstrated more hematologic malignancies in patients treated with lenalidomide as maintenance (vs placebo). This fact has prompted concern and highlighted the association between multiple myeloma and second malignancies. Furthermore, an excess of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) after multiple myeloma has been known for over 4 decades. Most prior studies have been restricted because of small numbers of patients, inadequate follow-up, and limitations of ascertainment of second malignancies. Although the underlying biologic mechanisms of AML/MDS after multiple myeloma are unknown, treatment-related factors are presumed to be responsible. Recently, an excess risk of AML/MDS was found among 5652 patients with IgG/IgA (but not IgM) monoclonal gammopathy of undetermined significance, supporting a role for disease-related factors. Furthermore, there is evidence to suggest that polymorphisms in germline genes may contribute to a person's susceptibility to subsequent cancers, whereas the potential influence of environmental and behavioral factors remains poorly understood. This review discusses current knowledge regarding second malignancies after multiple myeloma and gives future directions for efforts designed to characterize underlying biologic mechanisms, with the goal to maximize survival and minimize the risk for second malignancies for individual patients.Keywords
This publication has 66 references indexed in Scilit:
- Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS)Blood, 2011
- Proportion of second cancers attributable to radiotherapy treatment in adults: a cohort study in the US SEER cancer registriesThe Lancet Oncology, 2011
- The relationship between multiple myeloma and occupational exposure to six chlorinated solventsOccupational and Environmental Medicine, 2010
- Obesity is associated with an increased risk of monoclonal gammopathy of undetermined significance among black and white womenBlood, 2010
- Second solid cancers after radiotherapy for breast cancer in SEER cancer registriesBritish Journal of Cancer, 2009
- Genome-wide association study to identify novel loci associated with therapy-related myeloid leukemia susceptibilityBlood, 2009
- MDM2 SNP309 and TP53 Arg72Pro interact to alter therapy-related acute myeloid leukemia susceptibilityBlood, 2008
- Risk of multiple myeloma and monoclonal gammopathy of undetermined significance among white and black male United States veterans with prior autoimmune, infectious, inflammatory, and allergic disordersBlood, 2008
- Improved survival in multiple myeloma and the impact of novel therapiesBlood, 2008
- Cytogenetically defined myelodysplasia after melphalan-based autotransplantation for multiple myeloma linked to poor hematopoietic stem-cell mobilization: the Arkansas experience in more than 3000 patients treated since 1989Blood, 2008